Is Galectin Therapeutics going out of business?

GALECTIN THERAPEUTICS INC (GALT) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

GALECTIN THERAPEUTICS INC (GALT) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $13.3M of cash and short-term investments against $34.0M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

4.3% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; 2 adverse event families are active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Filing event risk: Going-Concern Warning, Clinical Trial Failure (-8 pts)
• Return on Assets: -207.99%
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 3.95% (YoY)

Read from filings through 2026-08-14.

Price as of 2026-09-07.